

Cancer Type	Diagnosis	Initial Staging	XRT Planning	Therapy Evaluation (interim)	Restaging After Therapy	Suspected Recurrence	Surveillance
ALL							
AML							
Anal		consider	X				
Bladder							
Primary Bone							
Chordoma		consider					
Chondrosarcoma							
Ewing Sarcoma		X			X		consider
Osteosarcoma		X			X		consider
Breast							
Noninvasive							
Invasive		Stage IIIA-IV: optional			optional		
Inflammatory		X			optional		
CNS	Guide Bx						
Anaplastic/GBM						consider	
Metastases		consider					
Lymphoma		consider					
Spinal mets		X					
Cervical		X	X			X	
CML							
Colorectal	No	Special Circumstances (see guideline)		No	No	Special Circumstances (see guideline)	No
Esophageal		X	X		X		X
Gastric		X	X		X		
Head/Neck	Occult Primary	X (for stage III/IV)			X		
Hepatobiliary							
HCC	Not adequate	Consider					
Gallbladder		Emerging evidence					
CholangiocA		Emerging evidence					
Hodgkin Lymphoma		X	X	X	X		No
Kidney							

Mesothelioma		X (before pleurodesis)	X				
Melanoma		X (see document for notes regarding specific stages)				X	X
Myeloma		X (if negative skeletal survey)			X	X	
Amyloidosis							
Waldenstrom							
Myelodysplastic							
Neuroendocrine	X (occult primary, poorly differentiated only)	X (Pheochromocytoma, Paraganglioma only)			X (Pheochromocytoma, Paraganglioma only)		
Non-Hodgkin Lymphoma		X	X	X (DLBCL)	X		
Basal / Squamous Skin Cancer							
DFSP							
Merkel Cell		As clinically indicated			As clinically indicated		
NSCLC	>8 mm noncalcified lung nodule	X	helpful		Possibly (difficult to interpret)		
Occult Primary	Warranted in Selected Scenarios						
Ovarian		If changes management			X	X	X
Pancreatic AdenoCA		Does not replace CE CT	helpful				
Penile		Consider if palpable inguinal nodes					
Prostate		FDG: Not routine NaF: accepted				FDG: not routine NaF: accepted Consider C11	

						choline	
SCLC		X (if limited stage suspected)	X				
Soft Tissue Sarcomas							
Ext/Trunk		Useful under certain circumstances					
RMS		X					
RP/Desmoid							
GIST		Consider		If CT ambiguous			
Testicular							
Seminoma					X (residual mass >3 cm)		As clinically indicated
Nonseminoma					No		No
Thymic		Optional					
Thyroid							
Papillary Follicular Hurthle Cell						Consider for RAI neg, Tg>2-5 ng/ml	
Anaplastic		X			X		
Uterine							
Endometrial		As clinically indicated					
Sarcoma		X				As clinically indicated	
Vulvar		As needed	X			As clinically indicated based on symptoms or exam findings	